FGFR1 and neoplasm: In recent years, molecular biology studies have revealed the presence of multiple key gene mutations in RGNTs [3], particularly mutations in the FGFR1 gene, which usually occur in its tyrosine kinase structural domain, leading to aberrant activation of the receptor and promoting cell proliferation and tumor formation through the RAS-MAPK signaling pathway.